Coherus BioSciences Reports Fourth Quarter and Full Year 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
Coherus BioSciences (CHRS) Misses Q4 EPS by 19c
February 27, 2020 4:27 PM ESTCoherus BioSciences (NASDAQ: CHRS) reported Q4 EPS of $0.53, $0.19 worse than the analyst estimate of $0.72. Revenue for the quarter came in at $123.9 million versus the consensus estimate of $123.01 million.
For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.
... More